Head to head
Semaglutide against AOD-9604
One of these failed its human weight loss trials and is sold anyway; the other is approved on trials in tens of thousands of people. AOD-9604 did not beat placebo in human obesity trials, and that is the comparison, not the difference in mechanism.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Column B
AOD-9604AOD-9604 (modified growth hormone fragment)
A modified fragment of growth hormone developed for obesity that promotes fat metabolism in animals but failed to beat placebo in human weight-loss trials.
Side by side, on the facts we can check
| Attribute | Semaglutide | AOD-9604 |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | Not an approved drug (failed obesity trials); GRAS notifications as a food ingredient |
| Half-life | ~7 days | Short |
| Molecular weight | 4,113.6 Da | ~1,815 Da |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Stimulates lipolysis and inhibits lipogenesis in fat cells in animal models, without meaningful effects on IGF-1 or blood glucose. |
| Human studies cited | 5 | 1 |
| Legal status, US | FDA-approved, prescription only | Not approved; research use only |
Frequently asked questions
What is the difference between Semaglutide and AOD-9604?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. AOD-9604: A modified fragment of growth hormone developed for obesity that promotes fat metabolism in animals but failed to beat placebo in human weight-loss trials.
Which has stronger research evidence, Semaglutide or AOD-9604?
This database does not grade compounds. It counts what was run in people: 5 of the 5 studies cited on the Semaglutide profile were human work, against 1 of 3 for AOD-9604. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Semaglutide and AOD-9604 FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). AOD-9604: Not an approved drug (failed obesity trials); GRAS notifications as a food ingredient.
Related posts
Blog articles that cover Semaglutide or AOD-9604, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.